Pacylex Publishes Phase 1 Safety and Efficacy of Zelenirstat in Cancer Patients in the Journal Investigational New Drugs

Edmonton, Alberta, Canada June 10, 2024. Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company developing N-myristoyltransferase (NMT) inhibitors to treat hematologic cancers and solid tumors. Today Pacylex announced the publication of Phase 1 clinical trial results in the journal Investigational New Drugs. The report, titled: "A First-in-Human Phase I Trial of Daily Oral Zelenirstat, a N-my